# Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT01550185** · PHASE1 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 10 (actual)

## Conditions studied

- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- Adult Acute Myeloblastic Leukemia With Maturation (M2)
- Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Adult Acute Myelomonocytic Leukemia (M4)
- Adult Erythroleukemia (M6a)
- Adult Pure Erythroid Leukemia (M6b)
- Recurrent Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** eltrombopag olamine
- **PROCEDURE:** standard follow-up care

## Key facts

- **NCT ID:** NCT01550185
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Sponsor wanted study rewritten
- **Last updated:** 2022-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01550185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01550185, "Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01550185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*